EyeCool Therapeutics key facts
- Developer of a novel device-based technology designed to focus on developing innovative treatments for Chronic Ocular Surface Pain (COSP).
- It has raised $12.5M; the latest was Angel (individual) in Dec 2024.
- Notable investors include PV Capital Management, Angel Physicians Fund, Catalyst Health Ventures, Excelestar Ventures, Hub Angels Investment Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch EyeCool Therapeutics: the Monday email on marks, rounds and moves
EyeCool Therapeutics funding rounds
No funding rounds for EyeCool Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
EyeCool Therapeutics investors
6 investors are on record for EyeCool Therapeutics, including PV Capital Management, Angel Physicians Fund, Catalyst Health Ventures and Excelestar Ventures.
About EyeCool Therapeutics
Developer of a novel device-based technology designed to focus on developing innovative treatments for Chronic Ocular Surface Pain (COSP). The company delivers a targeted, precise dose of thermal energy to transform the experience of COSP patients and the product workflow integrates into current clinical workflows, ensuring efficient and effective patient care, enabling the healthcare industry to provide fast and lasting relief for patients suffering from this condition.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 10
- Website
- eyecooltx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
EyeCool Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.